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Brief Summary: 
322 HIV-positive inpatients with tuberculosis were characterised. 2-month mortality was 31%, and 
dissemination was common. Older age, being male, taking antiretroviral therapy at admission, poor 
nutritional status and positive urine-diagnostics were associated with mortality. Interventions to 
reduce mortality are needed. 
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Abstract:  
Background: TB is the major killer of people living with HIV globally, with suboptimal diagnostics and 
management contributing to high case-fatality rates.   
Methods: A prospective cohort of confirmed (Xpert MTB/RIF and/or Determine TB-LAM Ag positive) 
TB patients identified through screening HIV-positive inpatients with sputum and urine diagnostics in 
Malawi and South Africa (STAMP trial). Urine was tested prospectively (intervention) or 
retrospectively (standard of care arm). We defined baseline clinical phenotypes using hierarchical 
cluster analysis, and also used Cox regression analysis to identify associations with early mortality 
(≤56 days). 
Results: Of 322 patients with TB confirmed between October 2015 and September 2018, 78.0% had 
≥1 positive urine test.  Antiretroviral therapy (ART) coverage was 80.2% among those not newly 
diagnosed, but with median CD4 count 75 cells/µL and high HIV viral loads. Early mortality was 
30.7% (99/322), despite near-universal prompt TB treatment.  Older age, male sex, ART before 
admission, poor nutritional status, lower haemoglobin, and positive urine tests (TB-LAM and/or 
Xpert MTB/RIF) were associated with increased mortality in multivariate analyses.  Cluster analysis 
(on baseline variables) defined 4 patient subgroups with early mortality ranging from 9.8% to 52.5%.  
Although unadjusted mortality was 9.3% lower in South Africa than Malawi, in adjusted models 
mortality was similar in both countries (HR 0.9, p=0.729). 
Conclusions: Mortality following prompt inpatient diagnosis of HIV-associated TB remained 
unacceptably high, even in South Africa. Intensified management strategies are urgently needed, for 
which prognostic indicators could potentially guide both development and subsequent use. 
 
Keywords: HIV, TB, hospital inpatients, mortality, urine LAM, Xpert 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
3 
 
Introduction 
HIV-associated tuberculosis disease (HIV/TB) is a leading cause of mortality, accounting for 370,000 
deaths globally in 2016 [1]. Much of this burden resides in patients admitted to hospitals in high HIV-
prevalence settings in Africa [2]. A meta-analysis estimated that TB caused 24% of admissions and 
27% of deaths amongst HIV-positive inpatients, with 30% case fatality [3]. Post-mortem data suggest 
an even greater burden, as almost half of fatal TB remains undiagnosed [4]. However, these data 
predate widespread access to antiretroviral therapy (ART) and improved diagnostics such as the 
Xpert MTB/RIF assay. 
There remains a scarcity of data on factors associated with mortality in HIV/TB. Post-mortems 
suggest TB as the predominant cause of death [4], but substantial co-morbidity from other 
opportunistic infections and non-infectious conditions means that death with confirmed TB does not 
necessarily imply death from TB. Observational cohorts report low CD4 cell count and older age as 
associated with mortality, but these data mainly relate to ART naïve individuals, and include patients 
without bacteriologically-confirmed TB disease [5–7]. Disseminated HIV/TB, as indicated by MTB 
detection in blood or urine, is also common and is an independent predictor of mortality [8–10]. 
Understanding factors associated with mortality in hospitalised patients with HIV/TB in the context 
of high ART coverage, rapid TB diagnostics with better yield, and prompt TB treatment could help 
inform strategies to identify high-risk patients, and interventions to reduce mortality. Here we 
describe characteristics of patients diagnosed with TB from the STAMP (Screening for TB to reduce 
AIDS related Mortality in hospitalised Patients) randomised controlled trial of urine-based TB 
screening in HIV-positive inpatients in Malawi and South Africa.[11] 
Our specific aims were to describe the clinical phenotypes, mortality and risk factors for mortality in 
hospitalised HIV/TB patients; the prevalence and mortality of disseminated TB; and the impact of 
ART and study site on mortality.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
4 
 
Methods 
This prospective cohort study was nested within the STAMP trial [11,12], which recruited adult HIV-
positive patients, irrespective of clinical presentation, at admission to medical wards in two hospitals 
in Malawi and South Africa. Upon enrolment, patients were randomised to TB screening using 
sputum testing alone (standard of care, SOC), or sputum and urine testing (intervention). Primary 
outcome was all-cause mortality at 2-months, and secondary outcomes included TB diagnosis and 
treatment. Patients were excluded if they had TB treatment within 12 months, isoniazid 
preventative therapy (IPT) within 6 months, unable to provide informed consent, or been admitted 
for >48 hours at the time of screening. 
Trial procedures are outlined in the Supplementary Methods [11,12]. After enrolment, urine and 
spontaneously expectorated sputum samples were obtained and tested for TB according to trial 
arm. Patients allocated to the intervention arm underwent sputum testing (if produced) with Xpert 
MTB/RIF assay (Xpert), unconcentrated urine was tested with Determine TB-LAM Ag assay (TB-LAM), 
and concentrated urine was tested with Xpert [13]. Patients allocated to the SOC arm had sputum 
Xpert testing only: with urine immediately frozen. Clinical events during admission were recorded, 
and patients followed-up once at 2-months by interview. Patients not attending follow-up were 
contacted by telephone and/or home visit, with interview of next-of-kin to establish vital status if 
necessary.  
Patients diagnosed with TB in the SOC trial arm (i.e. no real-time urine TB testing) had TB-LAM and 
Xpert testing performed on stored urine (Supplementary Methods). Patients were enrolled in this 
sub-study if they were diagnosed with TB and had positive laboratory tests (≥1 positive specimen on 
microscopy for AFB, Xpert, culture or TB-LAM) on any sample. Patients diagnosed or treated for TB 
without positive tests were excluded. The study was approved by the research ethics committee of 
the London School of Hygiene & Tropical Medicine, and local research ethics committees in Malawi 
and South Africa. 
Definitions 
Patients were defined as ‘clinically suspected TB’ if TB was recorded in the admitting differential 
diagnosis. Disseminated urinary TB was defined by any positive urine TB assay (TB-LAM or Xpert), 
and non-disseminated TB was a positive sputum TB assay with negative urine TB assays.  
A urine ‘TB score’ was calculated based on the number of positive urine TB tests (TB-LAM or Xpert, 
possible values 0-2) [14]. The Supplementary Methods outlines other definitions. 
 
Statistical analysis 
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Mortality risk was calculated 56-days from admission. All baseline demographics, clinical variables, 
laboratory results and physiological measurements were considered for association with mortality 
using Cox proportional hazards models. An explanatory model was built excluding the most proximal 
factors on the causal pathway to mortality (notably, functional impairment). Separate models were 
built to assess associations of recruitment site with mortality. Models used step-wise backward 
elimination (variables with p>0.1 were excluded) and were restricted to complete cases. Non-
linearity of continuous variables was assessed using fractional polynomials.  
Clinical phenotypes of HIV/TB patients were identified using unsupervised (i.e. without mortality 
outcome) hierarchical cluster analysis, with the number of clusters determined by stopping rules. 
Clusters were then described by comparing means and proportions to the overall population, and 
associations with mortality assessed using Kaplan-Meier curves, and Cox regression. Supplementary 
Methods describe the analysis in further detail. 
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Results 
Patient characteristics 
Between October 2015 and September 2017, 506 HIV-positive patients were diagnosed with TB, of 
whom 322 were laboratory-confirmed and included in this analysis. Similar numbers were from 
Malawi (155, 48.1%) and South Africa (167, 51.9%), with two-thirds (63.7%) clinically suspected to 
have TB (Table 1).   
At admission, median CD4 cell count was 75 cells/µL, and 93% had advanced HIV (as defined by 
WHO). 139 (43.2%) patients had ≥1 WHO danger sign, and 77 (23.9%) had signs of sepsis. Patients 
had substantial functional impairment, with 165 (51.2%) being unable to perform usual activities and 
74 (23.0%) assessed as severely disabled (Karnofsky score ≤40), and poor nutritional status (median 
BMI 18.2). Anaemia was very common, only 30 (9.3%) patients had normal haemoglobin and 62 
(19.3%) had life-threatening anaemia (haemoglobin <6.5 g/dL).  
267 (82.9%) patients knew their HIV status before admission, of whom 214 (80.1%) were taking ART. 
Median duration taking ART was 1.0 year (interquartile range [IQR] 0.3-4.2) and 68 (21.1%) were on 
ART for <3 months. Most (58.4% [125/214]) patients reporting current usage had been taking ART 
for ≥6 months, although their median CD4 cell count was only 96 cells/µL (IQR 32-319). HIV viral load 
results were available for 97/125 patients on ART for ≥6 months; 48 (49.5%) had >1000 copies/mL 
(median 557,000 copies/mL), highly suggestive of ART failure. 
TB characteristics 
TB diagnostic results are outlined in Table 2. Most (242/322, 75.2%) patients could provide sputum 
for Xpert testing. Disseminated urinary TB was common (78.0%, 251/322). When restricted to 
patients in the trial intervention arm, 181/212 (85.4%) patients had disseminated TB. One-third 
(34.2%, 86/251) of disseminated urinary TB patients were positive on both urine TB-LAM and Xpert 
assays.  
Of 197 patients undergoing chest radiography, 107 (54.3%) were interpreted by clinicians as 
consistent with TB. Only four patients (8.9% of those with CSF results) were diagnosed with TB 
meningitis, of whom all had positive urine TB tests (3 Xpert positive, 1 TB-LAM positive). 
Patients with disseminated TB were less likely to report a cough or to be clinically suspected of 
having TB. They were predominantly male and had more functional impairment (bedbound, unable 
to perform usual activities, and lower Karnofsky score); worse nutritional status (lower BMI and 
MUAC); were more likely to have WHO danger signs, sepsis and severe anaemia at presentation; and 
had lower CD4 cell counts (Table 1).  
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Eleven patients died before TB treatment initiation, while for those treated, median time from 
admission to treatment was 2 days (IQR 1 day). Four (1%) patients stopped TB treatment during 
hospitalisation due to treatment side-effects. Eleven patients were diagnosed with rifampicin-
resistant TB: six from sputum Xpert only, four from urine Xpert only, and one on both urine and 
sputum Xpert. 
Mortality 
Overall, 99 (30.7%) patients died by 56-days. Six patients were lost to follow-up after discharge. 
Mortality in HIV/TB patients did not differ by STAMP trial arm (p=0.30), consistent with mortality 
benefit in the trial being restricted to patients with missed TB diagnoses (and therefore not included 
in this analysis) [11]. Median time to death was 12 days (IQR 5-27), and 71.7% (71/99) occurred 
during admission, with 9 (9.1%) within 48 hours and 32 (32.3%) within 7 days of admission 
(Supplementary Figure 1). 
Mortality was lowest in patients with negative urine TB tests (19.7% by 56-day), compared to 
disseminated urinary TB with one (30.5%) or two (40.7%) positive urine tests (p=0.018). Reduced 
functional ability (lower Karnofsky score, self-reported reductions in mobility, self-care and usual 
activities) and poor nutritional status (MUAC and BMI) were strongly associated with mortality 
(Table 3). Mortality was also associated with lower CD4, haemoglobin and renal impairment, 
although not with WHO danger signs.  
In the multivariable model (n=320, Table 3), mortality was independently associated with advancing 
age, male gender, lower MUAC, lower haemoglobin and higher urine TB score. CD4 cell count was 
not independently associated with mortality.  
Not taking ART at admission was associated with a lower mortality than taking ART at admission in 
an unadjusted model (HR 0.6, p=0.035, Supplementary Figure 2), despite those taking ART having a 
lower median CD4 count (39 cells/µL [IQR 13-122] compared to 84 cells/µL [IQR 29-244]). Although 
unadjusted mortality was 9.3% lower in patients from the South African site, in an adjusted model 
mortality was similar to those patients from Malawi (adjusted hazard ratio [HR] 0.9, p=0.729, 
supplementary table). 
Clinical Phenotype 
Cluster analysis identified four distinct groups of patients based on correlation of clinical features at 
admission. Although not informed by outcome data, mortality differed substantially between these 
groups (Figure 1, HR 2.4 for group 2, 4.5 for group 3 and 6.7 for group 4 compared to group 1, 
p<0.001). Group 1 (lowest mortality risk, 9.8% [5/51]) were more likely to be ART naïve, have better 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
8 
 
functional status and nutrition (higher MUAC and BMI), less severe anaemia and higher CD4 cell 
count. Patients in group 2 (moderate mortality risk, 22.6% [23/102]) were characterised by a longer 
time on ART and almost half reporting normal physical function.  
Groups 3 and 4 (highest mortality risks, 37.1% [39/105] and 52.5% [31/59] respectively) patients all 
reported problems with usual activities, most had WHO danger signs and severe anaemia, and men 
predominated. Median CD4 counts were 78 and 38 cells/µl respectively. Clinical phenotype was also 
strongly associated with disseminated TB: groups 3 and 4 had the highest proportion of urine-
positive patients (83% and 86% respectively compared to 55% in group 1, p<0.001). 
Non-TB management 
Broad-spectrum antibiotics (ceftriaxone, amoxicillin-clavulanic acid or co-trimoxazole) were given to 
86.0% (277/322) of patients, with median duration 6 days (IQR 4-7 days). 45.1% (125/277) received 
two or more different antibiotics. 10.6% (10/94) of patients tested were cryptococcal antigen 
positive. Median duration of hospital stay was 10 days (IQR 5-15 days). Of the ART naïve patients 
surviving to discharge, 65.3% (49/75) commenced ART during the study, with median time to 
starting ART being 19 days (IQR 9-29). ART was started in 66.7% (14/21) of those who had 
discontinued ART, and 8.3% (1/12) ART naïve patients who died during admission.  
14.8% (37/250) of patients discharged were readmitted to hospital during the 56-day follow-up, with 
readmission associated with higher mortality (24% vs 9%, p=0.006). Outpatient attendance was also 
common, with patients discharged having a median of 2 (IQR 1-4) clinic attendances by 56 days. 
Patients dying after discharge were less likely to attend outpatient clinics (median 0 attendances 
[IQR 0-1] compared to 3 [IQR 1-4] for survivors, p<0.001). 
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Discussion 
The main findings were that two-month mortality in patients with HIV-associated TB was substantial 
(31%) despite good ART coverage, TB screening and prompt TB treatment. Urine diagnostic tests 
(likely defining disseminated TB) were positive in 78.0% of TB patients, and were associated with 
higher mortality. Despite most patients being established on ART, advanced immunosuppression 
and poor virologic control were common, and we report higher mortality in patients taking ART at TB 
diagnosis. Hierarchical cluster analysis defined four distinct clinical phenotypes with highly variable 
mortality (9.8% to 52.5%), suggesting that baseline risk-profiles could be used to prioritise patients 
for intensified care.  
Our observed early mortality is close to that estimated for HIV-associated TB from other studies 
[3,15], and was high in both South Africa (25.5%) and Malawi (34.8%). This 9.3% unadjusted risk 
difference indicates the magnitude of effect that could be attributed to the better resources in South 
Africa (upper middle income) compared to Malawi (low income). Irrespective of cause of admission, 
HIV-positive inpatients do badly, with early mortality risks of 20-30% reported consistently for sub-
Saharan Africa [16]. However, patients with disseminated TB do consistently worse than others. In 
the STAMP trial, for instance, HIV-positive inpatients without confirmed TB had 2-month mortality of 
16.5%, below that of urine-positive TB, although similar to TB diagnosed only through sputum [11].  
In this context, TB-LAM or urine Xpert positivity was associated with a severely ill clinical phenotype. 
This was also observed in a South African cohort, where markers of TB dissemination were 
associated with increased immune activation, which may contribute to mortality through tissue 
damage and organ dysfunction [15]. If we assume that positive urine results provide more rapid, less 
costly, and more sensitive equivalent of mycobacteraemia [15,17,18], then these simple prognostic 
markers could be used to target additional interventions to reduce mortality, as well as being used 
for TB diagnosis.  
TB patients taking ART ≥6 months had median CD4 count of only 96 cells/µL, with half having high 
viral loads (median 557,000 copies/mL). This strong relationship between disseminated TB and 
immunosuppression in patients taking ART prior to admission suggests that urine-positive TB could 
be an indicator of ART treatment failure. With successful scale-up of HIV-diagnosis and ART, the 
case-mix of inpatients has changed from predominantly ART-naïve [19] to that reported here: 80% 
with a known HIV-diagnosis taking ART. Interesting, this corresponds with a reversal in the 
prognostic value of ART prior to TB diagnosis, from beneficial [20,21] to a risk-factor for mortality 
[22]. Therefore, patients with TB should be immediately evaluated and managed for virological 
failure. However, facilities for rapid viral load testing are not universally available in inpatient 
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settings [23]. Also, the impending roll-out of Dolutegravir in the region may impact the degree of 
ART failure seen amongst inpatients [24]. 
Using both regression and cluster analysis, we found more severe functional impairment, worse 
nutritional status and severe anaemia being associated with both higher mortality and disseminated 
HIV/TB. Our findings support those reported in seriously ill HIV-positive inpatients with cough, where 
functional impairment (but not all WHO danger signs) were associated with poor outcomes [22]. The 
remarkably high mortality (50%) in those reporting severe functional impairment highlights the 
importance of upstream interventions to prevent TB, support early diagnosis, and improve 
recognition of critically-ill patients in community settings. Most patients reached their critically-ill 
state despite attending HIV-care services: empowering patients to promptly seek care could 
contribute to better outcomes.  
Intervening to avert mortality in HIV/TB patients after admission maybe challenging (table 4). 
However, only one-third of deaths occurred within 1 week, suggesting a potential window of 
opportunity. The best strategy for supportive care in African hospitals with high HIV and TB-
prevalence remains unclear, with early fluid resuscitation leading to increased mortality in patients 
with sepsis [25]. Although provision of broad-spectrum antibiotics in our cohort was almost 
universal, resistance to first-line antibiotics in study hospitals is now commonplace, especially in 
Enterobacteriaceae through extended spectrum β-lactamases [26]. Although Schutz et al [15] found 
TB, rather than bacterial coinfection, as the major cause of mortality in HIV-positive inpatients, 
empirical antimicrobial agents have been associated with lower mortality in advanced HIV [27]. 
Future strategies should account for antimicrobial resistance, and also target TB related mortality, 
for instance trialling high-dose rifampicin and/or host-directed therapies [28,29]. 
Cryptococcal meningitis is also a common cause of death in advanced HIV, and may be associated 
with HIV/TB [30,31]. D spite exclusion of patients with altered conscious level, CrAg positivity was 
over 10%, supporting screening and treatment of cryptococcal infection in this population. Anaemia 
has previously been associated with poor outcomes in HIV/TB [32], and this was also shown in this 
study. There are currently no normative guidelines on managing anaemia or blood transfusion in 
HIV/TB, and further research is needed before recommendations can be made [33].  
Almost one-third of deaths occurred after discharge, and those who died were less likely to attend 
outpatient clinics for follow-up. One-third of ART-naïve patients discharged alive had not 
commenced ART by 2-months, despite guidelines advocating early ART. This supports more intensive 
follow-up and support at discharge as a possible intervention to reduce mortality. Weekly follow-up 
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was part of an intervention which reduced mortality in patients with low CD4 counts starting ART, 
and warrants evaluation in HIV/TB [34].  
The strengths of this study include its being nested within a TB screening trial, that management was 
undertaken by routine health services, and that these data reflect the high ART coverage for the 
Southern Africa region. Limitations include suboptimal sensitivity of the TB screening algorithms, 
notably for the sputum-only arm of the parent trial. Our definition of confirmed TB included some 
patients who were only TB-LAM positive, and we cannot exclude a small number of false positives 
[35,36]. Sputum induction, which has been shown to increase the yield of sputum Xpert, was not 
available in this study [37]. Finally, we do not have post-mortem data. 
In summary, we have shown high mortality in hospitalised patients with HIV-associated TB despite 
current public health interventions. Urine diagnostics provide useful prognostic and well as 
diagnostic information, and could be used to guide the development and targeting of intensified 
inpatient management strategies. HIV/TB inpatients in this region now predominantly affects 
patients established on ART with advanced immunosuppression likely to indicate ART failure. This 
population will be important to meet both EndTB and UNAIDS 2020 and 2025 targets for reducing TB 
deaths. Early diagnosis and management of ART failure is one of several potential interventions that 
could improve survival of patients hospitalised with TB. Implementation is needed in parallel with 
further research and upstream public health interventions. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
12 
 
Funding 
This STAMP trial was funded by the Joint Global Health Trials Scheme of the Medical Research 
Council, the UK Department for International Development, and the Wellcome Trust 
[MR/M007375/1]. AG-W has received a Royal College of Physicians London JMGP Fellowship, ELC 
has received a Wellcome Trust Fellowship [WT200901/Z/16/Z]. 
Conflicts of Interest 
J.J.v.O. reports grants from London School of Tropical Medicine and Hygiene.  All other authors have 
no potential conflicts to disclose.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
13 
 
References 
1.  World Health Organization. Global tuberculosis report 2017. Geneva: 2017.  
2.  Nliwasa M, MacPherson P, Gupta-Wright A, et al. High HIV and active tuberculosis prevalence 
and increased mortality risk in adults with symptoms of TB: a systematic review and meta-
analyses. J Int AIDS Soc 2018; 21:e25162.  
3.  Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality 
among people living with HIV worldwide : a systematic review and meta-analysis. J Int AIDS 
Soc 2016; 19:20714.  
4.  Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies 
of HIV-infected adults and children in resource-limited settings: a systematic review and 
meta-analysis. AIDS 2015; 29:1987–2002.  
5.  Marcy O, Laureillard D, Madec Y, et al. Causes and determinants of mortality in HIV-infected 
adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized 
trial. Clin Infect Dis 2014; 59:435–45.  
6.  Holtz TH, Kabera G, Mthiyane T, et al. Use of a WHO-recommended algorithm to reduce 
mortality in seriously ill patients with HIV infection and smear-negative pulmonary 
tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 2011; 11:533–
40.  
7.  Manabe YC, Nonyane BAS, Nakiyingi L, et al. Point-of-care lateral flow assays for tuberculosis 
and cryptococcal antigenuria predict death in HIV infected adults in Uganda. PLoS One 2014; 
9:e101459.  
8.  Crump J a, Ramadhani HO, Morrissey AB, et al. Bacteremic disseminated tuberculosis in sub-
saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55:242–50.  
9.  Gupta-Wright A, Peters JA, Flach C, Lawn SD. Detection of lipoarabinomannan (LAM) in urine 
is an independent predictor of mortality risk in patients receiving treatment for HIV-
associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC 
Med 2016; 14:53.  
10.  Lawn SD, Gupta-Wright A. Detection of Lipoarabinomannan (LAM) in urine is indicative of 
disseminated tuberculosis with renal involvement in patients living with HIV and advanced 
immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg 2016; 110:180–185.  
11.  Gupta-Wright A, Corbett EL, Oosterhout JJ van, et al. Rapid urine-based screening for 
tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, 
multicentre, parallel-group, double-blind, randomised controlled trial. Lancet 2018; 392:292–
301.  
12.  Gupta-Wright A, Fielding KL, van Oosterhout JJ, et al. Rapid urine-based screening for 
tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP 
trial): study protocol for a randomised controlled trial. BMC Infect Dis 2016; 16:501.  
13.  Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of tuberculosis from screening 
urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert 
MTB/RIF assay. J Acquir Immune Defic Syndr 2012; 60:289–94.  
14.  Kerkhoff AD, Barr DA, Schutz C, et al. Disseminated tuberculosis among hospitalised HIV 
patients in South Africa: A common condition that can be rapidly diagnosed using urine-
based assays. Sci Rep 2017; 7:1–11.  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
14 
 
15.  Schutz C, Barr D, Andrade BB, et al. Clinical, microbiologic, and immunologic determinants of 
mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort 
study. PLOS Med 2019; 16:e1002840.  
16.  Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with 
HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2:e438–e444.  
17.  Lawn SD, Kerkhoff AD. Rapid diagnosis of TB in HIV-positive in-patients with M. tuberculosis 
bacteraemia in sub-Saharan Africa. Int J Tuberc Lung Dis 2015; 19:1557–9.  
18.  Barr DA, Kerkhoff AD, Schutz C, et al. HIV-associated M. tuberculosis blood stream infection is 
under-diagnosed by a single blood culture. J Clin Microbiol  2018;  
19.  Meintjes G, Kerkhoff AD, Burton R, et al. HIV-related medical admissions to a South African 
district hospital remain frequent despite effective antiretroviral therapy scale-up. Med 2015; 
94:1–10.  
20.  Kirenga BJ, Levin J, Ayakaka I, et al. Treatment outcomes of new tuberculosis patients 
hospitalized in Kampala, Uganda: A prospective cohort study. PLoS One 2014; 9:1–10.  
21.  Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and 
predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. 
PLoS One 2012; 7:e32876.  
22.  Griesel R, Stewart A, van der Plas H, Sikhondze W, Mendelson M, Maartens G. Prognostic 
indicators in the World Health Organization’s algorithm for seriously ill HIV-infected 
inpatients with suspected tuberculosis. AIDS Res Ther 2018; 15:1–9.  
23.  Craik A, Patel PP, Patel PP, et al. Challenges with t rgeted viral load testing for medical 
inpatients at Queen Elizabeth Central Hospital in Blantyre, Malawi. Malawi Med J 2016; 
28:179–181.  
24.  Dorward J, Hamers RL. Dolutegravir in sub-Saharan Africa: context is crucial. Lancet HIV. 
2019; 6:e72–e73.  
25.  Andrews B, Semler MW, Muchemwa L, et al. Effect of an early resuscitation protocol on in-
hospital mortality among adults with sepsis and hypotension: A randomized clinical trial. 
JAMA - J Am Med Assoc 2017; 318:1233–1240.  
26.  Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in bloodstream 
infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. Lancet 
Infect Dis 2017; 17:1042–1052.  
27.  Hakim J, Musiime V, Szubert AJ, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for 
Advanced HIV Infection in Africa. N Engl J Med 2017; 377:233–245.  
28.  Peloquin CA, Velásquez GE, Lecca L, et al. Pharmacokinetic Evidence from the HIRIF Trial To 
Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother 2017; 
61.  
29.  Zumla A, Chakaya J, Hoelscher M, et al. Towards host-directed therapies for tuberculosis. Nat 
Rev Drug Discov 2015; 14:511–512.  
30.  Jarvis JN, Harrison TS, Corbett EL, Wood R, Lawn SD. Is HIV-associated tuberculosis a risk 
factor for the development of cryptococcal disease? AIDS 2010; 24:612–614.  
31.  Karat AS, Omar T, Von Gottberg A, et al. Autopsy prevalence of tuberculosis and other 
potentially treatable infections among adults with advanced HIV enrolled in out-patient care 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
15 
 
in South Africa. PLoS One 2016; 11:1–16.  
32.  Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker L-G, Lawn SD. The predictive 
value of current haemoglobin levels for incident tuberculosis and/or mortality during long-
term antiretroviral therapy in South Africa: a cohort study. BMC Med 2015; 13:70.  
33.  Kerkhoff AD, Lawn SD, Schutz C, et al. Anemia, blood transfusion requirements and mortality 
risk in human immunodeficiency virus-infected adults requiring acute medical admission to 
hospital in South Africa. Open Forum Infect Dis 2015; 2:ofv173.  
34.  Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-
based early adherence support in people with advanced HIV infection starting antiretroviral 
therapy in Tanzania and Zambia: An open-label, randomised controlled trial. Lancet 2015; 
385:2173–2182.  
35.  Lawn SD, Kerkhoff AD, Burton R, et al. Diagnostic accuracy, incremental yield and prognostic 
value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected 
patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Med 
2017; 15:67.  
36.  Nel JS, Lippincott CK, Berhanu R, Spencer DC, Sanne IM, Ive P. Does Disseminated 
Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow 
Assay Results? A Retrospective Review. Clin Infect Dis 2017; 65:1226–1228.  
37.  Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of 
urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. Int J Infect Dis 
2018; 75:67–73.  
 
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1133/5645290 by guest on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
16 
 
Table 1: Baseline characteristics in laboratory confirmed HIV/TB patients, overall and stratified by 
disseminated urinary TB. 
 
 
All HIV/TB 
(n=322) 
Disseminated TB  
p-
valueb Yes (n=251) No (n=71) 
n %a n %a n %a 
Age Mean 37.2 10.5 36.8 10.3 38.7 11.3 0.175 
Gender Male 175 54.3% 131 52.2% 44 62.0% 
0.144 
 Female 147 45.7% 120 47.8% 27 38.0% 
Site Malawi 155 48.1% 131 52.2% 24 33.8% 
0.006 
 South Africa 167 51.9% 120 47.8% 47 66.2% 
Smoking Current 35 10.9% 26 10.4% 9 12.7% 
0.009 
 Former 77 23.9% 51 20.3% 26 36.6% 
Co-morbidity Yes 65 20.2% 49 19.5% 16 22.5% 0.577 
New diagnosis of HIV Yes 55 17.1% 43 17.1% 12 16.9% 0.964 
ART statusd Naïve 34 12.7% 25 12.0% 9 15.3%  
 Current 214 80.1% 165 79.3% 49 83.1% 0.167 
 Interrupted 19 7.1% 18 8.7% 1 1.7%  
Time on ART (years)e Median 1.5 5.0 0.9 4.2 1.6 5.2 0.962 
Second-line ART e Yes 6 2.8% 2 2.5% 4 4.1% 0.547 
Cough Yes 234 72.7% 175 69.7% 59 83.1% 0.026 
Fever Yes 228 70.8% 182 72.5% 46 64.8% 0.206 
Night Sweats Yes 170 52.8% 136 54.2% 34 47.9% 0.348 
Weight Loss Yes 293 91.0% 227 90.4% 66 93.0% 0.513 
≥1 WHO TB symptom positive 317 98.4% 247 98.4% 70 98.6% 0.911 
Duration of illness 
(days) 
Median 14 21 14 21 14 21 0.873 
Previous TB Treatment Yes 73 22.7% 53 21.1% 20 28.2% 0.21 
EQ5D mobility Some problems 163 50.6% 129 51.4% 34 47.9% 
0.067 
 Confined to bed 77 23.9% 65 25.9% 12 16.9% 
EQ5D self-care Some problems 129 40.1% 107 42.6% 22 31.0% 
<0.001 
 
Unable to wash/ 
dress 
86 26.7% 75 29.9% 11 15.5% 
EQ5D usual activities Some problems 91 28.3% 72 28.7% 19 26.8% 
0.002 
 
Unable to 
perform 
165 51.2% 138 55.0% 27 38.0% 
EQ5D health score Mean 52.1 13.6 48.0 14.2 54.0 11.4 <0.001 
BMI Median 18.2 5.0 18.0 4.6 19.4 6.2 0.049 
MUAC Median 20 5.5 20 4.5 21 6.5 0.039 
Karnofsky score Median 50 10 50 20 60 20 0.001 
 ≤40 74 23.0% 65 25.9% 9 12.7% 0.019 
Blood pressure Median SBP 102  101  106  0.009 
 Median DBP 67  66  70  0.060 
Heart Rate Mean 104.7 20.8 105.5 21.1 101.8 19.5 0.189 
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Respiratory rate Mean 23.3  22.8  23.4  0.265 
Oxygen saturations (%) Median 96 4 96 4 96 4 0.991 
WHO danger sign Yes 139 43.2% 117 46.6% 22 31.0% 0.019 
Sepsis Yes 77 23.9% 69 27.5% 8 11.3% 0.005 
Haemoglobin (g/dl) Mean 8.8 27.7 8.4 26.1 10.2 28.9 <0.001 
Anaemia Severe 133 41.3% 115 45.8% 18 25.4% 
0.001  Moderate 117 36.5% 91 77.8% 26 22.2% 
 Mild 42 13.1% 27 64.3% 15 35.7% 
CD4 count Median 74.5 182 61 157 129 295 0.002 
 <100 188 58.4% 155 61.8% 33 46.5% 0.017 
C- reactive protein Median 138 112 141.5 106 117 136 0.619 
WHO stage 1 or 2 35 10.9% 28 11.2% 7 9.9%  
 3 111 34.5% 78 31.1% 33 46.5% 0.052 
 4 176 54.7% 145 57.8% 31 43.7%  
Clinically suspected TB  Yes 205 63.7% 147 58.6% 58 81.7% <0.001 
Data are numbers and % unless otherwise stated. a If variable is median represents interquartile 
range, if variable is mean represents standard deviation. b Comparing disseminated TB yes/no, 
calculated using Chi-squared for proportions, t-test for means and Wilcoxon rank sum for medians. d 
restricted to patients with known HIV diagnosis. e restricted to patients reporting current ART use. 
Missing data: 1 missing haemoglobin, 2 missing second-line ART regimen, 93 missing C-reactive 
protein. ART is antiretroviral therapy, WHO World Health Organization, EQ5D EurQol 5 Dimension, 
BMI Body Mass Index, MUAC mid-upper arm circumference, SBP systolic blood pressure, DBP 
diastolic blood pressure. Heart rate and respiratory rate are measured per minute. 
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Table 2: TB investigations and results 
TB investigation n=322 % 
Sputum   
Sample sent for TB testing 242 75.2 
Xpert positive 168 52.2 
Urine    
Sample sent for TB testing 
TB-LAM positive 
321 
209 
99.7 
66.1 
Xpert positive 128 40.5 
Any urine TB test positive 251 78.0 
Urine TB score   
0 71 22.0 
1 165 51.2 
2 86 26.7 
Chest radiography    
     Underwent chest radiography 197 61.2 
    Clinicians report as “consistent with TB” 107 33.2 
Cerebrospinal Fluid (CSF)a   
Tested 45 14.0 
Consistent with TB 4 1.2 
Rifampicin resistant TB   
Xpert rifampicin result available (sputum or urine) 223 69.3 
Rifampicin resistance detected 11 4.9 
% are based on all patients (n=322) as the denominator. Sputum includes study TB screening and 
routine clinical samples. aCSF testing consistent with TB includes lymphocytes with raised protein or 
positive Xpert. One patient missing data for CSF testing. CSF is cerebrospinal fluid, Xpert is Xpert 
MTB/RIF assay, TB-LAM is Determine TB-LAM Ag assay. TB score calculated based on the number of 
positive urine TB tests (TB-LAM or Xpert, possible values 0-2). 
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Table 3: Factors associated with time to death over 56 days 
Characteristic 
Deaths 
(n=99) 
Mortality 
risk (%) 
Univariable  Multivariable  
HR 
Lower 
CI 
Upper 
CI 
p-value 
 
HR 
Lower 
CI 
Upper 
CI 
p-value 
Age   1.02 1.00 1.03 0.073  1.03 1.01 1.05 0.003 
Sex     Female 35 23.8 1     1    
Male  64 36.8 1.74 1.15 2.63 0.007  1.77 1.01 2.70 0.008 
Site    Malawi 54 34.8 1     
- 
   
South Africa 44 25.5 0.78 0.53 1.16 0.217     
ART    Currently taking 80 34.3 1     
* 
   
Not currently taking 19 21.6 0.60 0.36 0.99 0.035     
Duration of illness        
* 
   
<7 days 28 22.6 1        
>7days 71 36.2 1.77 1.14 2.74 0.008     
EQ5D mobility#        
- 
   
No problems 9 11.0 1   
<0.001 
    
Some problems 51 31.5 3.21 1.58 6.52     
Confined to bed 99 50.7 6.26 3.03 12.93     
EQ5D self-care#        
- 
   
No problems 10 9.4 1   
<0.001 
    
Some problems 47 36.4 4.63 2.34 9.17     
Unable to wash/dress 42 48.8 6.86 3.44 13.68     
EQ5D usual activities#        
- 
   
No problems 5 7.6 1   
<0.001 
    
Some problems 29 32.2 5.05 1.96 13.06     
Unable to perform 65 39.4 6.30 2.54 15.65     
EQ5D health score#   0.97 0.96 0.99 <0.001  -    
BMI   0.96 0.91 1.01 0.086  -    
MUAC   0.87 0.82 0.92 <0.001  0.89 0.83 0.94 <0.001 
Karnofsky#   0.96 0.95 0.98 <0.001  -    
WHO danger sign        
- 
   
No 51 27.9 1        
Yes 48 34.8 1.34 0.90 1.99 0.146     
Haemoglobin$ (g/dL)   0.86 0.80 0.93 <0.001  0.88 0.81 0.95 0.002 
CD4 count (cells/µL)   0.93 0.88 0.99 0.022  *    
eGFR$ ≥60ml/min 17 25.0 1     -    
 <60ml/min 15 51.7 2.45 1.23 4.93 0.013      
C-reactive protein$ (mg/L)   1.01 1.00 1.01 0.043  -    
WHO clinical stage        
- 
   
1 or 2 7 20.0 1        
3 28 25.5 1.36 0.60 3.12 0.031     
4 64 36.4 2.14 0.98 4.66      
Able to produce sputum             
No 32 40.0 1         
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Yes 67 27.8 0.66 0.43 1.0 0.061  *    
TB-LAM            
Negative 29 25.9 1     -    
Positive 70 33.5 1.72 1.00 2.95 0.044      
Urine Xpert positive            
Negative 49 25.3      -    
Positive 50 39.4 1.91 1.28 2.87 0.002      
Urine TB score   1.84 1.05 3.24 0.024  1.41 1.03 1.91 0.025 
Hazard ratios (HR) calculated using Cox proportional hazards models. Continuous variables were all 
modelled as linear after checking for departures from linearity. For continuous variables, HR is for every 
unit increase in the variable, except for CD4 count where HR is for every 50 cells/µL increase. Urine TB 
score was modelled as a continuous linear variable. All p-values calculated using likelihood ratio testing. 
$Missing data: 1 missing haemoglobin, 93 missing C-reactive protein, 225 missing eGFR. #Variable 
excluded from multivariable model as distal on causal pathway to death. CRP and eGFR were excluded 
from the multivariable model due to >25% missing data. The following variables were excluded due to 
collinearity: BMI was colinear with weight; WHO stage was colinear with CD4 count; TB-LAM and urine 
Xpert were colinear with urine TB score. All other variables with p>0.1 in univariable analysis were 
entered into the multivariable model using backwards stepwise elimination (variables exited the model 
if P>0.1), n=321. *Variables eliminated from the multivariable model. ART is antiretroviral therapy, BMI 
Body Mass Index, CI confidence interval, eGFR estimated glomerular filtration rate, EQ5D EurQol 5 
Dimension, HR Hazard Ratio, MUAC mid-upper arm circumference, WHO World Health Organization.
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Table 4: Implications and potential interventions to reduce HIV/TB mortality 
Issue Evidence for 
association with 
HIV/TB mortality 
Possible interventions Further research/ 
unanswered questions 
ART failure  Higher mortality in 
ART experienced 
patients 
 Low median CD4 
counts and high 
viral loads in 
patients taking 
ART >6 months 
 
 Rapid screening for 
virological failure at 
admission (eg using 
point-of-care HIV viral 
load assay) 
 Adherence interventions 
or switch to second-line 
ART 
 Integrase inhibitors (few 
drug-drug interactions 
with TB medication) 
 Prevalence of HIV drug 
resistance 
 Timing of ART switch in 
HIV/TB patients failing 
ART 
 Optimal regimen for 
switching 
TB during early 
ART 
 One-fifth of 
HIV/TB patients 
were within 3 
months of ART 
initiation 
 High mortality  
 
 Improved TB screening at 
ART initiation 
 Better implementation of 
TB preventative therapy 
 
 Best approach for TB 
screening in ART naïve 
patients (eg TB-LAM, 
Xpert and/or chest 
radiography) 
 Implementation 
research for TB 
preventative therapy 
 
Supportive 
care and co-
morbidities 
 WHO danger signs 
and sepsis are 
common 
 10% cryptococcal 
antigenemia 
 Life-threatening 
anaemia has high 
mortality 
 28% of deaths 
after discharge 
 
 Screening, treatment 
and/or prophylaxis for co-
infection 
 Improved supportive care 
 More intensive follow-up 
post discharge from 
hospital 
 
 Prevalence of bacterial 
co-infection and AMR 
 Evidence for safety and 
efficacy of supportive 
care (eg IV fluids and/or 
blood transfusion) 
 Impact of enhanced 
follow-up on outcomes, 
and frequency of visits 
 
Identification 
of high risk 
patients 
 Clinical phenotype 
associated with 
high mortality 
 Urine diagnostics 
associated with 
higher mortality 
 
 Predictive tools to 
identify patients at higher 
risk of mortality who may 
benefit from 
interventions (eg clinical 
risk score) 
 Derivation and 
validation of prognostic 
score 
 Use of score(s) for 
implementation of 
interventions aimed at 
mortality 
 
ART is antiretroviral therapy, TB is tuberculosis, AMR is antimicrobial resistance. 
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Figure Legends 
Figure 1: Cluster analysis clinical phenotypes of HIV/TB patients and their mortality risk 
A is a heat map comparing characteristics of clinical phenotype groups (from cluster analysis) to the 
overall population. Overall n=317, group 1 n=51, group 2 n=102, group 3 n=105, group 4 n=59. For 
continuous variables (marked with *), colours represent a ratio of mean or median values for the 
group compared to the overall mean or median. For categorical variables, the ratio is the group 
proportion compared to the overall proportion. Dark purple (    ) represents a ratio >1.6, and white (   
) represents a ratio <0.4. Missing data: 1 missing haemoglobin, 2 missing second-line ART regimen, 
93 missing C-reactive protein, 222 missing HIV viral load. EQ5D variables are the proportion 
reporting ‘no problem’. Time on ART and second-line ART are restricted to patients reporting current 
ART use. 
B Kaplan-Meier plot of time to death by clinical phenotype group. Grey dashed vertical line 
represents median length of hospital stay (10 days). Hazard ratio (HR) compared to group 1 is 2.4 
(95%CI 0.9-6.3) for group 2, 4.5 (95%CI 1.8-11.4) for group 3 and 6.7 (95%CI 2.6-17.3) for groups, 
p<0.001. 
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Figure 1 
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